SHANGHAI, April 15, 2015 /PRNewswire/ -- WuXi PharmaTech
(Cayman) Inc. (NYSE: WX) today announced that it filed its annual
report on Form 20-F for the year ended December 31, 2014, with the Securities and
Exchange Commission. The annual report can be accessed on
WuXi PharmaTech's website at http://www.wuxiapptec.com under the
Investor Relations section. WuXi PharmaTech will provide a
hard copy of its annual report on Form 20-F containing complete
audited financial statements free of charge to its shareholders and
ADS holders upon request. Requests should be directed to
Ronald Aldridge, Director of
Investor Relations, by email at ron_aldridge@wuxiapptec.com.
About WuXi PharmaTech
WuXi PharmaTech (NYSE: WX) is a leading
open-access R&D capability and technology platform company
serving the pharmaceutical, biotechnology and medical device
industries, with operations in China and the United
States. As a research-driven and
customer-focused company, WuXi PharmaTech provides a broad and
integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi
is also building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. WuXi
PharmaTech's services are designed to assist its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. WuXi PharmaTech's operating subsidiaries are
known as WuXi AppTec. For more information, please visit:
http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for
investors)
Director of Investor Relations
+1-201-585-2048
Email: ron_aldridge@wuxiapptec.com
Aaron Shi (for the media)
Director of Corporate Communications
+86-21-5046-4362
Email: aaron_shi@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatech-files-2014-annual-report-on-form-20-f-300066255.html
SOURCE WuXi PharmaTech (Cayman) Inc.